Table 2.
Pregnancies with paternal exposure to anakinra or canakinumab at conception
| Diagnosis | Number of offspring exposed | Drug/dose | Drug duration prior to conception (months) | Congenital abnormalities | Developmental abnormalities | Gender | Age at last contact |
|---|---|---|---|---|---|---|---|
| AOSD | 1 | Anakinra 100 mg daily | Not known | None | None | Female | 4 weeks |
| AOSD | 1 | Anakinra 100 mg daily | Not known | None | None | Female | 10 months |
| CAPS | 3 | Canakinumab 150 mg 8 weekly | 248 | None | None | Male | 10 years |
| 75 | None | None | Male | 8 years | |||
| None | None | Female | 4 years | ||||
| CAPS | 1 | Anakinra 100 mg daily | 25 | None | None | Male | 8 years |
| CAPS | 1 | Canakinumab 150 mg 8 weekly | 23 | None | None | Male | 7 years |
| TRAPS | 2 | Anakinra 100 mg alternate days | 3 | None | None | Male | 5 years |
| 57 | None | None | Female | 6 months | |||
| TRAPS | 1 | Anakinra 100 mg daily | 66 | None | None | Male | 16 months |
| TRAPS | 1 (IVF) | Canakinumab 150 mg 8 weekly | 24 | None | None | Female | 2 years |
AOSD: adult onset stills disease; CAPS: cryopyrin-associated periodic fever syndromes; IVF: in vitro fertilization; TRAPS: TNF receptor-associated periodic fever syndrome.